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In the past two decades, microfluidics-based particle production has been widely applied for 
multiple biological usages. Comparing to conventional bulk methods, microfluidic-assisted 
particle production shows significant advantages, such as narrower particle size distribution, 
higher reproducibility, improved encapsulation efficiency and enhanced scaling-up potency. In 
this review, we provide an overview of the recent progress of the microfluidics technology for 
nano-, micro-particles or droplet fabrication, and their biological applications. For both nano-, 
micro-particles/droplets, we discuss the previously established mechanisms behind particle 
production via microfluidics and highlight some typical examples during the past five years. 
The emerging interdisciplinary technologies based on microfluidics that have produced 
microparticles or droplets for cellular analysis and artificial cells fabrication are summarized. 






Particles and droplets production is one of the most indispensable and fundamental process in 
biomedical engineering field, and have been widely applied in controlled drug 
delivery/release,[1] vaccination,[2] tissue engineering,[3] biosensors and diagnostic devices,[4] 
bio-imaging,[5] cellular analysis and artificial cells fabrication.[6, 7] Based on the size scale, 
particles can be divided into nano- and micro-particles and droplets. Yet, a better clinical 
translation of such nano-, micro-particles is highly dependent on the reproducible and scalable 
synthesis and production methodology, which can be barely concurrently achieved with bulk 
methods, such as high pressure homogenization (HPH), sonication or static mixer.[8] As such, 
a sophisticated alternative method should be further applied to better control the production of 
nano-, micro-particles. 
In past decades, the concept “Lab-on-Chip” facilitated the evolving development of continuous 
and more precise systems for healthcare applications.[9] As a fundamental regime, 
microfluidics—a technology characterized by the manipulating nanoliters scale of fluids in 
submillimeter channels— has become an innovative alternative approach to the bulk method in 
the biomedical field.[10] It has been widely applied in 3D cell cultures, single cell analysis, 
cell/molecule isolation and purification, body fluidic stream simulation, organ-on-chip, nano-, 
micro-fibers production, and nano-, micro-particles production.[11] 
Microfluidics assisted particles and/or droplets production has drawn increasing attentions due 
to its several advantages including high reproducibility, low batch-to-batch variation, better 
control over particle characters and easy to scale-up. We identified the most frequent keywords 
associated with scientific articles using a word extraction procedure applied on a large database. 




years. We investigated changes in the frequency and order of appearance of the most frequent 
keywords extracted between two time periods: (i) 20092013 and (ii) 20142019. We adapted 
the R code (scopusapi.R) from https://github.com/christopherBelter/scopusAPI to implement a 
query on the word “microfluidics”, using Scopus Search application programming interface 
(API) in R software [quote R here]. For each time period, we kept a maximum of 2000 most 
relevant downloaded records. We further queried the API, using an advanced search string to 
extract the authors’ keywords, and computed their frequency of appearance, and ranked the 
keywords according to their frequency. Figure 1 (left panel) shows two cloud plots that 
highlight words that appear more than 10 times, and the top 25 most frequent words are shown 
Figure 1 (right panel). These results suggest that, despite their observed decrease in frequency 
in the later period, cellular analysis and microdroplet-based single cell analysis remain the most 
prevailing applications for microfluidics. We also noticed frequency changes between the 
investigated periods. For example, the word “drug” (ranked 12th in 20092013) became 3rd in 
20142019, and the word “delivery” only appeared on the “20142019 billboard”. Furthermore, 
ranking for the word “capillary” shifted from 11th (20092013) to 8th (20142019) position and 
the word “paperbased” solely appeared on the top 25 most frequent words in 20142019, which 
may suggest a recent tendency for microfluidic chip fabrication. In addition to that, there are 
several words that only appeared in the 20142019 cloud plot, such as “particle”, “engineering”, 
“imaging”, “culture”, “film”, and “phase”, indicating increasing interests in using microfluidics 
for particle fabrication and engineering. 
In this review, we will briefly describe recent advances of microfluidic-produced particles 
and/or droplets for biomedical applications. Dependent on the size of the produced particles, 




phase flow microfluidics; and micro-particles/droplets, which are fabricated via multi-phase 
flow microfluidics. We will separately describe the previously established mechanism behind 
the microfluidics-assisted nano-, micro-particles or droplets production to better illustrate the 
advantages of the current systems. Moreover, we will highlight some recent publications using 
microfluidics-based nano-, micro-particles for multiple biomedical applications. For 
nanoparticles, we will focus on their microfluidics-assisted production with identical core/shell 
structure. For micro-particles/droplets, we will mainly highlight microfluidics-produced micro-
particles/droplets for biological analysis or simulation, which are inspired by the evolving 
molecular biological concepts and techniques, such as single cell analysis and/or artificial cells. 






Figure 1. Visualisation of the most frequent words from author keywords of scientific papers 
using Scopus Search “microfluidics” over two time periods: (a) 20092013 and (b) 20142019. 
The left panel (cloud plot) highlights words that appear more than 10 times, and the right panel 
lists the top 25 frequent words screened from author keywords. 
 
2. Microfluidic production of nanoparticles 
2.1. Advantages of microfluidics for synthesis of nanoparticles (NPs) 
Producing nanoparticles via the microfluidics method is not a new story. It has long been 
reported that the continuous synthesis of NPs by using microfluidics obtained better 




mainly due to the mechanism of NPs formation and the unique fluid dynamics in the 
microfluidic systems. 
In a typical NPs synthesis, the procedure is based on a bottom-up approach, where most of the 
theoretical work describing the formation process of the NPs are based on the classical 
nucleation theory. In 1950, LaMer et al. proposed the concept of burst nucleation, which 
described the formation of NPs as: (1) a rapid increase in the concentration of free monomers 
in solution, inducing a specific supersaturation level; (2) energy barrier for nucleation is 
overcame, leading to the burst nucleation; (3) burst nucleation rapidly decrease the 
supersaturation level, resulting in the termination of further nucleation; and (4) secondary 
growth occurs at the particle surfaces by diffusion facilitated monomer flux.[13] Following work 
has enriched the theory by providing refined interpretation of both the growth and size 
narrowing processes. For example, Reiss deduced that the size focusing phenomenon from NPs 
formation was due to the diffusion induced growing of particles, which is solely dependent on 
the size of NPs where smaller NPs obtain a faster growth rate.[14] Later on, Lifshitz, Slyozov 
and Wagner made a major advance by introducing the Ostwald ripening theory for interpreting 
the coarsening phenomenon of the particles (LSW theory).[14, 15] Ostwald ripening is the process 
by which small particles shrink, due to enhanced solubility arising from their high curvature, 
and larger particles grow. Ostwald ripening is commonly invoked to explain the particle aging, 
coarsening and stability, and readers may refer the following papers to have a further 
knowledge.[16] So far, the LaMer’s model and its following refinements are still the most 
commonly accepted models describing the NPs formation.[17, 18, 19] 
The commonly accepted mathematical equation describing the nucleation is based on the Gibbs 




 ΔG = − 4
3
πr3|ΔGv|+ 4πr
2γ                                                  (1) 
and, ΔGv is further defined in Eq. (2): 
 ΔGv = 
-kBT ln(S)
ν
                                      (2) 
where ΔGv stands for free energy of the cluster, r stands for the spherical particle radius, γ stands 
for the surface energy per unit area, kB stands for the Boltzmann’s constant, S stands for the 
supersaturation level of the solution and ν stands for the molar volume of the monomer. When 
the radius of a nucleus reaches to a critical value (rc), ΔG achieves the maximum value (energy 
barrier), thus the further growth of the cluster is favored (
dΔG
dr
 < 0, Figure 2a). This further gives 
the critical radius, as defined in Eq. (3): 
 rc = 
2νγ
kB T ln(S)
                                     (3) 
The nucleation rate (
dN
dt
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where, A is the pre-exponential factor and T is the temperature. 
Nucleation critically impacts the quality of the formed NPs, as nucleation rate is positively 
correlated to the nuclei density, which will further result in smaller NPs and enhanced particle 
yield.[20-22] Based on Eq. (3), controllable parameters (T, S and γ) can be varied to influence the 




to S = 4 could cause an increase in the nucleation rate about ∼1070, and at room temperature (≈ 
300 K), even slight temperature change could induce changes of several orders of magnitude in 
the nucleation rate (Figure 2b-d).[18]  
In order to achieve homogeneous kinetics, the NPs nucleation and growth process should be 
preferably initiated in a homogenous solution, which means the mixing time of 2 solvents, tmix, 
must be less than the time scale for the nucleation initiation, tini. In a typical amphiphilic block 
polymer nucleation procedure, the relevant time scale for initial structure formation can be 
under 100 ms for molecules of 100000 g mole-1.[23] However, from a practical point of view, 
bulk methods usually fail to create a homogenous condition within the orders of milliseconds.[24] 
As such, the local supersaturation level of the monomers within the solution may be vastly 
altered, and as a sequelae, results in a lower monodispersity and higher batch-to-batch 
variation.[22, 25, 26]  
Microfluidics, a technology characterized by the engineered manipulation of fluids at the 
submillimeter scale,[27, 28, 29] can sharply increase the surface area-to-volume ratio by several 
orders of magnitude, and therefore, allows for more efficient mass and heat transfer within the 
system. More importantly, microfluidic chips with specific modification and specific flow 
diameter can achieve the mixing time on the order of milliseconds, rendering a tmixing < tini 
regime, further yielding the particle formation within a homogeneous solution. The flow-
dominated mixing within the microfluidic channel provides better reproducibility and 
controllability compared to batch-type bulk mixing. Such feature makes the microfluidics a 






Figure 2. (a) Free energy diagram of nucleus for describing the nucleation process. ΔG, Gibbs 
free energy of a nucleus; ΔGc, energy barrier; rc, critical radius of the nucleus with maximum 
free energy. (b) Nucleation rate as functions of supersaturation. (c) Nucleation rate as function 
of the temperature. (d) Nucleation rate as function of surface free energy calculated using Eq. 
(4), which v is set as 3.29 × 10−5 m3 mol−1, the value for CdSe NPs. The nucleation rate is 
normalized with the pre-exponential factor A. Figures are reproduced with permissions from: 
(a) ref. [19], Copyright 2015, Royal Society of Chemistry; and (bd) ref. [18], Copyright 2011, 
Wiley-VCH. 
 
2.2. Methodology for manipulating the NPs production using microfluidics 
2.2.1. Alert the flow pattern within the microfluidics chip 
Under a fixed formula for producing specific NPs, the parameters for the synthesized NPs (e.g., 
size and polydispersity index, PDI) are highly implicated with the mixing efficiency of a 




microfluidics that contribute to the mixing efficiency.[31] Diffusion refers to the random motion 
of solutes driven by a gradient in chemical potential and convection refers to the mixing caused 
by the convective motion of fluids.[32] In engineering, the behavior of liquids is often described 
in terms of dimensionless numbers which compare the importance of different physical 
properties. The Peclect number (Pe) is a commonly applied dimensionless number for mass 
transfer processes, which relates the rate of advection of a flow to its rate of thermal diffusion. 
Higher Pe values indicate a more important role of convective bulk flow within the mixing.[33] 
This can be expressed as Eq. (5):[34] 
 Pe = VD⁄d                                    (5) 
where, V is the total flow speed within the microfluidics channel, D is the hydraulic cross-
sectional diameter of the channel and d is the mass diffusion coefficient of the solute. For a 
typical microfluidic channel with the a diameter less than 10-3 m, a typical Pe number ranging 
from 102 to 104 can be observed from two commonly used miscible fluids systems such as 
ethanol and water,[35] suggesting that convection dominates the mixing procedure. To better 
understand and explain convection within the flow, considering that the extent of convection is 
mainly dominated by the fluidic pattern in the microfluidics channel, one considers an 
additional dimensionless parameter, the Reynolds number (Re), which is defined in Eq. (6):[36] 
 Re = ρQ⁄ηD = Q⁄νD                            (6) 
where, ρ is the density of the fluid, Q is the total flow rate of the fluid, η is the viscosity of the 
fluid, ν is the kinematic viscosity of the fluid and D is the hydraulic diameter of the channel. 
Re compares inertial and viscous forces, and a decreased Re always follows that inertia 
generally becomes unimportant.[32] Considering viscosity produces a resistance to shear and the 




stochastic fluidic pattern, ultimately resulting in a shift from laminar-to-turbulent flow. As 
laminar flow only yields fluidic moves in smooth layers, whereas turbulent flows are 
characterized by chaotic motion of fluid elements and seemingly random fluctuations in 
instantaneous velocities. Despite the difficulty in predicting and modeling fluid mechanics in 
turbulent flow, the mixing efficiency within the turbulent regime is vastly enhanced, and is 
therefore preferred for NPs synthesis. 
One method to increase the mixing efficiency is by enhancing the Re within the mixing channel. 
Kim et al. have long confirmed that increasing values of the Re alter the vortex pattern within 
the microfluidics channel (Figure 3a) and this further affects the size of the NPs produced 
(Figure 3b), regardless relatively low maximum values of the Re (Re = 150).[37] Farokhzad et 
al., on the other hand, pushed the Re within the microfluidics channel up to 1311. Different 
types of NPs, including polymeric NPs (polylactic-co-glycolic acid-polyethylene glycol 
(PLGA-PEG) and polystyrene (PS), liposomes to metal nanoclusters (iron oxides) were 
synthesized in a polycarbonate based micro-jetting device.[28] Under a fixed flow rate between 
inner and outer fluids (Rin/out), with the increase of Re, a departure from the laminar flow 
velocity profile, and the emerging presence of micro-vortex, and ultimately to turbulent jetting, 
was observed (Figure 3c-e). It should be noted that the conventional transitional Re (Ret), 
which refers to laminar flow in a circular pipe becomes naturally turbulent at a critical Reynolds 
number, is usually observed at around 2000 to 2300.[38] However, in microfluidics, a clear 
turbulent flow can be achieved with a Re lower than 500.[39] Peng et al. first reported that the 
transition to turbulence occurred at Re as low as 200–700 in the microchannels with hydraulic 
diameters of 133–367 μm,[40] which were similarly observed by other groups.[41] They attributed 
this phenomenon to the decreased diameter and increased surface roughness of the channel. 




calculation within microfluidic channels in further detail.[39] Despite the controversial 
conclusion about the Ret within microfluidics channel and corresponding flow pattern,
[42] 
simply by manipulating the flow rate/ratio to alter the Re, one can fabricate NPs with 
significantly enhanced homogeneity comparing to the bulk method. Previous results suggested 
that at a total flow rate of 8.3 mL h-1, the total mixing of two phases will take place in dozens 
of seconds.[43] However, the turbulent flow regime, mixing time (tmix) is tunable in the range of 
7–53 ms by changing the Re, which is considerably lower than the typical nucleation time (tnul) 
of polymer (∼1–100 ms, depending on the molecular weight of the chain).[12, 20] 
Liu et al. further applied a computational fluidic dynamics (CFD) method to illustrate the 
microfluidics mixing at different flow regime.[26, 44] At the flow regime of laminar flow or 
microvortex flow (Re up to 200), an evaluated mixing efficiency and NPs homogeneity can also 
be achieved along with the enhanced Re and it is mainly due to an amplified microvortices in 
the microfluidics channel along with the increase of Re (Figure 3f).[26] With the further increase 
of Re (Re > 500), the flow regime will transit to turbulent jet, and due to the ultra-fast flow rate, 
microscopic observation may fail to detect the violent flow domain changes,[45] and a 
computational turbulent flow model can be applied to overcome the limitations.[44] As can be 
seen in Figure 3g, at the Re = 500 and 1300, a turbulent flow was simulated, which is indicated 
by the disappearance of a coaxial jet and complete fluids mixing less than 1 ms, confirming the 
flow behavior can be feasibly tailored by manipulating the flow rate/ratio.[44] 
The main advantages for manipulating the Re to control the NPs size/morphology includes, for 
example, simple fabrication of the chip, easy prediction, and fast operation. Moreover, in the 
perspective of biomedical applications, the sharply increased flow rate will simultaneously 




reach a NPs production rate above 242.8 g/day, which meets the requirements for industrial-
scale NPs production,[26, 28] hence facilitating industrialization and clinical translation. 
However, the accompanied drawbacks mainly come from the ultra-high flow rate induced by 
this method. In a typical microfluidic channel with the inner diameter of 1 mm, a total flow rate 
of 5256 mL h-1 should be obtained to achieve the Re of 1300. And the first constraint therefore 
may come from the maximum force of the fluidic pump, and the corresponding microfluidic 
device should show suitable pressure resistance. And at this high flow rate, block and stagnation 
of the channel may cause serious sequential issues. Meanwhile, due to the ultrahigh flow rate, 
the parameters (such as flow rate, concentration of the starting materials and surfactant etc.) 
optimization process usually need excessive materials consumption, and therefore may not be 
suitable for fabricating nanosystems that contain expensive compounds such as proteins, 





Figure 3. (a) The microvortex within the microchannel can be manipulated by adjusting the 
parameter values to obtain Re values suitable for NPs production, thus size-controllable NPs 
syntheses can be achieved through variation of the Re. Microvortex patterns are both predicted 
by the CFD simulations and visualized by microscopic images. (b) Size map of the produced 
NPs by varying the Re with given PLGA-to-lipid weight ratios. (c) Macroscopic images of flow 
pattern alteration obtained by increasing the total flow rate. (d) Phase diagram of the flow 
regime in terms of flow rate ratio (R) and Re. (e) Quantitative measurement of the reduced 




flow regime (laminar flow), with the enhanced Re, a larger microvortex can be generated in the 
microchannel, thus inducing a better mixing efficiency. (g) CFD simulation confirmed the ultra-
high mixing efficiency with the flow regime transiting to turbulent flow (Re = 500, 1300). 
Figures are reproduced with permissions from: (ab) ref. [37], Copyright 2012, American 
Chemical Society; (ce) ref. [28], Copyright 2014, American Chemical Society; (f) ref. [26], 
Copyright 2015, Wiley-VCH; (g) ref. [44], Copyright 2017, American Chemical Society. 
 
2.2.2. Alter the geometry of the mixing channel 
The other commonly used method is typically based upon smart design of the channel 
geometries. Various types of microfluidic chips with complex geometry, such as Tesla-shape,[46] 
herringbone-shaped,[47, 48] serpentine-shaped,[49] , planar asymmetric split,[50] spiral/semi-
spiral,[51, 52] zigzag-shaped channel etc.,[53] were designed and applied for preparing NPs 
(Figure 4a-e). For example, herringbone-shaped microchannel containing patterned 
microgrooves of varying shapes and angles can induce chaotic stirring at a low Re (Re = 10-2-
102). At relatively low total flow rate (600 μL min-1), the efficient mixing time remains on the 
order of milliseconds (~8 ms) by applying this apparatus.[48] Complex geometry can decrease 
the mixing length at relatively low Re, thus achieved a thorough mixing at low flow rate, 
therefore more suitable for precise production of costly NPs. For example, Tokeshi et al. 
recently applied a multi-baffles integrated microfluidics chip to produce siRNA-loaded 
liposomes. The newly designed chip showed a non-inferior mixing efficiency compared to 
herringbone-shaped chip (fully mixing at the flow rate of 500 μL min-1). More importantly, for 
the first time it was reported liposomes size tuning at 10 nm intervals in the size range from 20 
to 100 nm (Figure 4f).[54] Not only by designing the geometry of the mixing chamber, Bokare 




fluids, the mixing efficiency can also be affected, as by integrating the herringbone-pattern with 
the inlet channel of a micro-cortex mixer (Figure 4g), the size of produced PLGA/lipid 
nanohybrids reduced from 199 nm to 74.5 nm.[55] 
Besides of influencing the size and morphology of NPs, as the altered geometry of microfluidic 
chips may impact on the mixing efficiency and shear force of the fluids,[56] thus the geometry 
of microfluidic chips may also dictate the internal crystallinities of the NPs. Moffitt et al. 
investigated the size, morphologies and crystallinities of polycaprolactone-block-poly(ethylene 
oxide) (PCL-b-PEO) NPs produced by single-phase staggered herringbone (SHB) mixer 
(featured with high mixing rate, but low shear force) or two-phase gas-liquid segmented mixer 
(featured with low mixing rate, but high shear force).[57] The results suggested that the 
morphologies, dimensions, and crystallinities of NPs produced in the single-phase SHB and 
two-phase mixer was similar in low flow rate regime (20 µL min-1), but showed a different 
feature at high flow rate regime (60 and 100 µL min-1), while the crystallinities of the NPs 
produced in the bulk method (featured with low mixing rate and low shear force) are similar 
with NPs produced in SHB (Figure 4h). These finding suggested that the mixing rate strongly 
affects the NPs morphologies and dimensions, and the mixing rate has a much weaker effect on 
the core crystallinities, which are mainly influenced by shear effects. 
One main disadvantage of the complex chip geometry design is that the chip usually involves 
subtle and precise channels. Therefore, the channels may easily get clogged during the NPs 
production, which leads to stagnation of the sample flow.[54] In addition, the accurate chip 
design usually lacks flexibility and robustness, especially regarding the microchannel aspect 
ratio when fabricating three-dimensional mixer structures.[54] Furthermore, to fabricate a 




polydimethylsiloxane (PDMS). PDMS is not resistant to many organic solvents, which may 
constrain its potential application in the producing of NPs.[58] For glass or silicon chips, despite 
their chemical inertness and optically transparent feature, standard photolithography to produce 
such devices is usually involved in dangerous chemicals (e.g., hydrofluoric acid). Also harsh 
conditions, including high temperature, high pressure and super clean environment, are 
commonly required for the bonding process.[59] As such, posing limits to their broad 
applications. 
 
Figure 4. (ae) Representative microfluidic chips with complex geometry used to achieve a 




limited mixing efficiency at various flow rate, and (a2) Tesla-shaped microfluidic chip can 
enhance the mixing performance for Re ranging from 0.1 to 100 (0.015–15 μL s-1). (b) Typical 
serpentine structured microfluidic chips for producing silver nanoparticles. (c) A typical 
microfluidic chip with patterned staggered herringbone geometry. (d) Mass-fraction 
distributions at Re=80 by applying planar asymmetric split and recombine microfluidic chip. 
(e) The mixing efficiency of zigzag-shape microfluidics chip can be altered by changing the 
amplitude ratio-to-wave length at a fixed inlet Re of 50. (f) Schematic illustration of the multi-
baffles integrated microfluidics chip and CFD simulation results for the flow rates of 50 and 
500 μL min-1. The application of the current chip can precisely control the produced liposomes 
at 10 nm intervals in the size range from 20 to 100 nm (right panel). (g) Geometry pattern of 
the inlet channel can also be modified to achieve better mixing efficiency. (h) The geometry 
pattern of the microfluidic can also affect the crystalline and morphology of the produced nano-
micelle. Figures are reproduced with permissions from: (a1) ref. [60], Copyright 2012, Elsevier; 
(a2) ref. [61], Copyright 2015, Elsevier; (b) ref. [62], Copyright 2019, Elsevier; (c) ref. [63], 
Copyright 2018, Elsevier; (d) ref. [50], Copyright 2013, Wiley-VCH; (e) ref. [64], Copyright 2014, 
Elsevier; (f) ref. [54], Copyright 2018, American Chemical Society; (g) ref. [55], Copyright 2019, 
American Chemical Society; and (h) ref. [57], Copyright 2016, American Chemical Society. 
 
2.2.3. External energy integrated microfluidic chips 
So far, efforts have been made to enhance the mixing in microfluidics by integrating outer 
sources of energy. The general idea is to introduce an external energy to agitate the fluid, as 
such enhancing the mixing efficiency. 




the fluid. Microfluidics chips can be integrated with piezoelectric ceramics, which operate at a 
high frequency in the kHz region, to locally generate pressure fluctuations in liquids and disturb 
the laminar flow pattern.[65] A better mixing efficiency can be achieved with a higher frequency 
or voltage excitation, however, it may induce unintended heating of the fluid. Yet it takes a few 
seconds to tens of seconds to achieve homogenous mixing.[66] Further methods applied side-
wall trapped microbubbles as a piezo transducer to form microstreaming, and successfully 
reduced the mixing time to less than 120 ms at a driving frequency of 81.4 kHz with the flow 
rate of 3 μL min-1.[67] Surface acoustic wave-powered microfluidic chips offer an alternative 
acoustic streaming source, which can further reduce the mixing time to 11 ms.[68]  
Other methods, such as applying pressure perturbation, dielectrophoresis induced dipole 
moment, pulsed/periodic electrodynamics actuation, and optics can extensively enhance the 
mixing efficiency, and thus, have been widely applied in biological samples’ analysis and bio-
synthesis, and readers may refer to an extensive review by Lee et al. for further information.[29] 
However, the fabrication of the corresponding chips is relatively complicated and expensive, 
and in addition the successful mixing usually needs the fluids to obtain special electrical 
properties, hence have been relatively less applied in the NPs fabrication. 
 
2.3. From simple to core/shell fabrication 
2.3.1. Synthesis and application of microfluidic-produced core/shell NPs 
There is a rich literature that provides reviews that focus on several aspects of the applications 
of microfluidics produced NPs for biomedical usages. For example, Luo et al. and Swider et al. 
reviewed the specific NPs productions within microfluidics such as inorganic NPs and PLGA 




translation of nanomedicine.[70] Sanjay et al. and Liu et al. summarized the application of 
microfluidics in synthesizing advanced drug release systems.[71] For the sake of brevity, the 
current review will mainly focusing on the NPs with identical core/shell structures and their 
corresponding applications. 
After the initial research work that mainly focused on using microfluidics to produce basic NPs 
for multiple biomedical applications, recent efforts have been made to fabricate nanohybrids 
that incorporate two or more nanomaterials.[72] Comparing to the conventional nanosystems,  
nanohybrids exhibit enhanced biocompatibility, stability, catalytic properties and hierarchical 
control.[73] Among which, nanohybrids with identical core/shell structures, such as 
organic/inorganic nanohybrids,[74] inorganic/inorganic nanohybrids[75] and lipid/polymer 
nanohybrids[52] have been widely investigated. The previous bulk methods used to produce 
core/shell nanosystems usually contains two independent steps to separately prepare the core 
structure and the sequential shell coating, and thus often exhibit poor control over the 
encapsulation efficiency and reproducibility. With the development of microfluidics, a 
continuous method combining the simultaneous and/or sequential nanoprecipitation of core 
NPs and shell coating showed considerable advantages by reducing intermediate disturbances 
and batch-to-batch variation.[76] Tables 1 and 2 briefly list the examples of the microfluidics 
used to produce core/shell structures over the past 5 years. In the following text we will 
highlight some of the cases. 
 
Table 1: Examples of single-step precipitation methods for producing core/shell NPs 
investigated from 2014-2019. 
Core 
Materials 
Shell Materials Inlet Fluid 1 
(F1) 
Inlet Fluid 2 
(F2) 






Fe3O4 NPs Purified red 
blood cells 
(RBC) vehicles 
0.4 mg mL-1 
Fe3O4 NPs in 
PBS buffer 
2.5 mL PBS 
containing 
RBC-vehicle 
from 0.2 mL 
of mouse 
blood 
20 μL min-1:20 μL 
min-1 
[77] 
Fe3O4 NPs Au NPs 21126 μg 
mL−1 as-
prepared 





1.5 mM) in 
H2O 
100 μL min-1:100 μL 
min-1 
[78] 
Fe2O3 NPs PLGA PLGA (5 mg 
mL-1) and 
Fe2O3 NPs in 
tetrahydrofura
n (THF) 












 AcDEX PSi (0.5 mg 
mL-1), Au NPs 





















PSi (1 mg mL-
1) dispersed 
into POD (15 
mg mL-1) in 
ethanol/H2O 
(80/20, v/v) 















H2O (pH = 8) n.s. [75] 
PSi NPs AcDEX 0.12 mg mL-
1 of PSi NPs 
dispersed in 






















1% PVA (pH 
8) aqueous 
solution 



























MW 520 kDa) 
EGaln 
solution 
0.5 M bPEG 
aqueous 
solution 














ELP (25 mg) 
mixed with 5 




n (THF) to 
adjusted to 15 
mg SPIONs 
per mL 











10 mg mL-1 

























mixed at a 
molar ratio of 
72:25:3 
(respectively) 
to a final lipid 
concentration 
of 13.6 mM in 
a solvent 
mixture (10.16 





























1 mg mL-1 
n.a.: not applicable; n.s.: not specified. 
 
Table 2: Examples of sequential precipitation methods for producing core/shell NPs 




First Mixing Shell 
Materia
ls 












8 mM CoCl2 
in 8 mM citric 
buffer 
0.1 wt-% PVP 
(55 kDa) + 
19.2 mM 
NaBH4 in H2O 




n.a. 15 mL h-
1:15 mL h-











0.078 g H2O + 
9.74 g IPA 
SiO2 1.148 g of 
ethylsilicate 
(TEOS) in 
8.7 g IPA 
0.758 g 
ammonia in 
2.84 g H2O 











0.48 mg mL-1 
cholesterol, 












3.5 mL of 
trifluoroeth
anol (TFE) 







100 mg PLGA 
in 6.5 mL 
DMF, and 





























v/v) at a mass 










ratio of 80: 
4: 16 










8 mM CuSO4 
in H2O 
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Changes targeting the composition of the fluidic channels suffice to achieve multiple 
hierarchical structures. Jiang et al. applied a two-stage microfluidic platform, which was 
composed of two consecutive nanoprecipitation devices (Figure 5a-b).[52, 91, 92] First, a PLGA 
solution is introduced into the first precipitation stage and lipid solution is injected into the 
second stage. Secondly, a PLGA/lipid-layer core/shell structure is formed by injecting lipid 
solution into the first precipitation stage, and the PLGA solution into the second stage in order 
to form the PLGA/liposome structure. The difference of their structure was confirmed by cryo-
transmission electron microscope (Cryo-TEM) and fluorescence quenching titration method. 
Computational molecular dynamics simulation was used to illustrate the encapsulation process, 




as such highlighting the consequence of changing shell materials in manipulating the 
physiochemical properties of the NPs.  
Based on this idea, core/shell structures were widely applied into encapsulating pre-existed NPs 
to improve their stability, biocompatibility and targeting ability. For example, Zhang et al. 
encapsulated prickly zinc-doped copper oxide nanoparticles with a carbonic anhydrase IX 
targeting ligand modified spermine-acetalated dextran (Spermine-AcDEX).[83] Comparing to 
the pristine NPs, the newly produced core/shell nanohybrids obtained a better human plasma 
stability (aggregation time 5 min vs. 120 min), a reduced toxicity towards normal fibroblast 
cells (3T3), but an enhanced targeting ability towards human breast cancer (MCF-7). Liu et al. 
encapsulated atorvastatin loaded porous silicon (PSi) NPs with a reactive oxygen species 
(ROS)-responsive polymer, 4-(hydroxymethyl)-phenylboronic acid pinacol ester conjugated 
oxidized dextran (POD) and further applied the nanosystem for diabetic wound healing.[81] The 
major obstacle for porous materials, burst payload release, can be overcome by the polymeric 
shell formation and the release kinetics can be feasibly tailored by the choice of the shell 
material, as the release of atorvastatin can only be triggered with the co-existence of over-
produced ROS, and the release rate can be sustained for over 24 h, making the core materials 
more suitable for envisioned biomedical applications. 
This “shell formation induced surface stabilization” concept may be further applied to control 
drug loading and release if the “core” is directly composed of drug nanocrystals. Recently, Liu 
et al. developed a microfluidics platform with two-consecutive precipitation processes, where 
the first-step precipitation produced drug nanocrystals dispersing in fully dissolved polymer 
solution (hypromellose acetate succinate, HF) by mixing drug acetone solution (10 mg mL-1) 




out by further mixing with acidic aqueous solution (pH 3), and thus, coating the drug 
nanocrystals in the second stage to form core/shell structures (Figure 5c).[44] The instability 
issue of drug nanocrystals was overcome by the superfast coating of the polymer, as a result of 
the high mixing efficiency at the Re of 1300. Ultra-high flow speed further achieved 
considerable throughput production rate (∼700 g per day on a single device) of the NPs. More 
importantly, the application of this platform increased the paclitaxel (PTX) loading degree from 
∼6.7% to 42.6% and sorafenib (SFN) loading degree from 6.2% to 45.2%, hence further 
potentiating the industrialization of nanomedicines. 
The choices for shell materials can vary from polymers, to inorganic materials and lipids. 
Recently, biomimetic cell membrane-coated NPs draw increasing attention due to their superior 
biochemical properties, including a reduction of the mononuclear phagocyte system uptake and 
vaccine adjuvants-like function.[95] Conventional methods, such as ultrasonic treatment and 
mechanical extrusion, may face obstacles like the inactivation of membrane proteins, 
destruction of NPs cores and the loss of NPs during the extrusion. Rao et al. demonstrated a 
microfluidic electroporation method to encapsulate Fe3O4 NPs using red blood cell (RBC) 
vesicles (Figure 5d).[91] Electroporation, defined as a technique applying electric pulses of 
intensity in kilovolts per centimeter and of duration in microseconds to milliseconds, may cause 
a temporary loss of the semi-permeability of cell membranes. This technique was integrated 
with microfluidics chips to generate hydrophilic pores in the RBC’s membrane.[96] RBC 
vesicles were harvested and purified to obtain a size of around 200 nm. Fe3O4 NPs (∼80 nm) 
and RBC vesicles were separately injected into two inlets, after converging at the Y-shaped 
channel, and sequential mixing through an S-shaped channel. The mixture of the two 
components flew through an electroporation zone and one outlet. The electric pulses effectively 




and flow velocity (50 V, 200 μs, and 20 μL min-1, respectively), one can achieve a complete 
coverage of the RBC’s membrane on the Fe3O4 NPs without inducing the electric field caused 
NPs aggregation.[96] 
In addition to form single core/shell structures, achieving a multi-hierarchical, multi-functional 
nanosystem, simultaneous co-encapsulation of two or more types of NPs with altered 
physiochemical properties within one matrix, is also in great demand. Liu et al. demonstrated 
the simultaneous co-encapsulation of PSi NPs (~200 nm) and gold (Au) nanoparticles (< 5 nm) 
into a single polymeric matrix, and further applied it for acute liver failure theranostic therapy 
(Figure 5e).[80] The application of PSi NPs enhanced the loading degree of a hydrophobic drug 
(2,4-((5,10-Dimethyl-6-oxo-6,10-dihydro-5H-pyrimido[5,4-b] thieno[3,2-e][1,4]diazepin-2-
yl)amino)benzenesulfonamide) from 0.04% to 7.8%, and co-residence of Au NPs endowed the 
system with the capability to function as a contrasting agent for computed tomography (CT) 
imaging. Moreover, the contradiction of designing Au NPs for CT imaging, namely, too small 
Au NPs (< 5 nm) suffer from low plaque accumulation, whereas large Au NPs showed higher 
cellular toxicity, which was solved by the robust encapsulation process. It should be noted that 
the successful co-encapsulation of both PSi NPs and Au NPs was dependent on tailoring the 
surface properties of the NPs, as the co-residence of both NPs (PSi NPs and Au NPs) in a single 
polymeric matrix can only be achieved by separately modifying their surface with 
SpermineAcDEX, which is a derivative of the shell polymer AcDEX. This further introduced 
the subjects for propose mechanical explanations to describe and predict the synthesis of 





Figure 5. (ac) Microfluidic-assisted sequential nano-encapsulation for continuously 
production of core/shell NPs. By altering the precipitation sequence, one can feasibly produce 
(a) PLGA NPs coated with lipid singe layer (up pannel), PLGA NPs coated with liposomes 
(down panel) or (b) Water@Lipid single layer@PLGA@Lipid single layer structures. (c1) 
Similar strategy can also be applied to encapsulate drug nanocrystals within enteric polymers 
to stabilize the drug nanocrystal, as well as the control the drug release behavior, which are 
confirmed by the TEM images of the produced (c2) PTX@hypromellose acetate succinate (HF) 




(d1) Application of electroporation-integrated microfluidic chip to produce RBC-vesicle 
encapsulated Fe3O4 NPs, and the TEM images of correspondingly produced nanohybrids (d2). 
(e1) Schematic presentation of microfluidic-assisted co-encapsulation of different NPs with 
different sizes (PSi NPs ~150 nm and Au NPs ~5 nm). (e2) The established method solely 
encapsulated one type of NPs or (e34) simultaneously encapsulated both type of NPs. Figures 
are reproduced with permissions from: (a) ref. [52], Copyright 2015, Wiley-VCH; (b) ref. [92], 
Copyright 2015, Wiley-VCH; (c) ref. [44], Copyright 2017, American Chemical Society; (d) ref. 
[77], Copyright 2017, American Chemical Society; and (e) ref. [80], Copyright 2017, Wiley-VCH. 
 
2.3.2. Recent progress in describing the microfluidic-produced core/shell NPs 
The mechanisms behind the formation of core/shell structures has been less investigated. One 
of the first trials with potential mechanical explanations was proposed by Karnik et al.[76] They 
tried to fabricate lipid/polymer nanohybrids with PLGA NPs core and lipid outer layers by using 
a microfluidic-assisted single-step encapsulation. PLGA in acetonitrile was used as the inner 
phase and lipid in ethanol/water was applied as the outer phase. The interesting phenomenon 
was, while keeping synthesizing parameters constant, that the size of the newly formed 
nanohybrid became smaller than both bare PLGA and bare liposomes. The phenomenon, as the 
authors hypothesized, was due to halting of PLGA NPs growth, which was caused by the lipid 
coverage at the hydrophobic surface of PLGA cores. Furthermore, and the pre-condition for the 
efficient lipid coating was the dispersion of lipid molecules within the mixing medium, which 
should be on the same time-order than the PLGA nucleation. A corresponding mathematical 
simulation and calculation were introduced to test the hypothesis, and the results showed that 




order of magnitude faster than the timescale for PLGA nucleation, suggesting the PLGA 
nucleation was initiated under a homogenized condition. In addition, the timescales of diffusion 
and binding between lipid and PLGA nucleates were on the same order as the PLGA nucleation, 
indicating the simultaneous lipid coating at the PLGA surface. 
Mathematical models have been developed to study and predict microfluidic-assisted core/shell 
structure formation. Gindy et al. applied multi-inlet vortex mixer (MIVM) to encapsulate 
colloidal Au NPs with a co-polymer (polyethylene glycol-caprolactone, PEG-PCL).[97] Since 
the final size of the yielded nanohybrids was positively correlated to the Au NPs concentration, 
the authors deduced that the encapsulation process could be described as a diffusional growth, 
where the Au NPs were treated as monomers and the final formation of nanohybrids were 
regarded as a process of coalescence (merging of particles), and followed by the monomers 
association induced size narrowing effect. Therefore, based on the colloid self-assembly in the 
diffusion-limited regime, the authors suggested a model, described in  Eq. (7):[97] 
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where, [PN] is the concentration of particles composed of N Au NPs, [P]0
tot
 is the monomer 
concentration at t = 0, and τ is given in (Eq. (8)):[97] 
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where, kB is the Boltzmann constant, T is the solution temperature, and µ is the solvent viscosity. 
At a fixed value of t and [P0] (initial number of monomers in solution), the aggregate 
distribution N×[PN]/[P0] can be represented by a function of the number of monomers N in 




timescale of multi-inlet vortex mixer (MIVM) is 3 ms, and the approximated nucleation time 
of PEG-PCL, on the other hand, is 37 ms. Based on Eq. 7, the average number of Au NPs within 
the nanohybrids at t = 40 ms can be calculated. Assuming the radius of each Au NPs monomer 
is 4 nm and the packing of the monomers within the nanohybrids is randomly close-packed 
with a volume fraction of 0.63, the size of the final yielded nanohybrids, as determined by the 
encapsulated number of monomers, can also be calculated. Experimental data were compared 
with calculated cluster diameters as a function of monomer concentration with sufficient 
correlation, and the predicted number of Au NPs within the polymeric matrix was also 
supported by the TEM images. 
More recently, Pagels et al. further expanded the model for τ described in Eq. 8 to be applied 
into a wider criteria.[98] The authors suggested a model, described in Eq. (9), to describe the 
core/shell formation, where the starting materials for composing the core are much smaller than 
the final core/shell nanohybrids. This can be observed during the polymeric encapsulation (shell) 
processes of hydrophobic drugs or hydrophobic polymers (core). In the study, both hydrophobic 
small molecules (vitamin E) and polymers (polylactide, PLA; polystyrene, PS) were 
successfully encapsulated by either PLA-PEG or PS-PEG. The experimental results revealed 
that the final size of the produced core/shell NPs was independent of the molecular weight of 
the core materials, which is one of the key feature for Smoluchowski diffusion-limited growth 
kinetics (Figure 6b).[99] As such, derived from the Smoluchowski growth kinetics, Eq. (9) can 
be used to predict the size of the yielded core/shell NPs: 
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temperature, kB is the Boltzmann constant, μ is the solvent viscosity, ρ is the bulk density of the 
core, and ccore is the mass concentration of the core material during particle assembly (one-half 
of the concentration at the beginning), cBCP is the mass concentration of the shell material during 
particle assembly (one-half of the concentration at the beginning), and K is a single scaling 
constant with the value 253 ms·g1/3 m-1. The main goal of Eq. (9) is to provide a mean for the 
size and drug loading optimization with a given hydrophobic compound. However, it should be 
noted that the key parameter within the Eq. (9), K, was summarized from the actual 
experimental data and the successful prediction may likely be dependent on the stabilizing 
hydrophilic polymer-block used. Nonetheless, considering the most commonly used stabilizer 
within this study (PEG), the simplicity of Eq. (9) remains a relevant model that can be easily 
applied to producenanohybrids.  
To understand the process to encapsulate the core NPs, Hasani-Sadrabadi et al. applied 
molecular dynamics (MD) simulations to delineate the paclitaxel  loaded chitosan core/Eudragit 
shell formation process.[94] A T-shaped microfluidics chip was coupled with a Tesla-shaped chip 
to produce core (chitosan)/shell (Eudragit FS 30D, poly(methyl acrylate-co-methyl 
methacrylate-co-methacrylic acid)) NPs. A 3D cell consisting of Eudragit and chitosan chains 
was fabricated by use of COMPASS (condensed-phase optimized molecular potentials for 
atomistic simulation studies) force field. After 600 picoseconds NVT (moles (N), volume (V), 
and temperature (T) are conserved for the canonical ensemble) MD simulations, the distance 
between Eudragit and chitosan layers in the equilibrated cell became closer, which was further 
corroborated by the binding energy, and the strong intermolecular hydrogen bonding 
interactions between Eudragit and chitosan, as such, provided further insights for interpreting 





Figure 6. (a) Based on the diffusion-limited colloid self-assembly model, a plot of aggregate 
distribution as a function of the number of Au cluster monomers in the aggregate is generated 
to predict the size of yielded nanohybrids at the fixed time of 40 ms. (b) The actual size of 
produced core/shell nanohybrids compared with the predicted size for a given formulation 
calculated from Eq. (9) (dash line), with a value of K = 253 ms·g1/3·m−1. (c) MD simulation 
was applied to study the interaction between Eduragit and chitosan. (c1) Initial structure and 
(c2) after 600 ps MD simulations. Optimized model structure of (c3) Eudragit; (c4-5) chitosan; 
(c6) Eudragit-chitosan cluster and (c7) hydrogen bonding between Eudragit and chitosan. (c8) 
Quantitative total electronic energy and zero-point energy of Eudragit, chitosan and Eudragit-
chitosan cluster. Figures are reproduced with permissions from: (a) ref. [97], Copyright 2008, 




ref. [94], Copyright 2016, Wiley-VCH. 
 
3. Microfluidic production of microparticles/droplets 
The aforementioned methods to prepare NPs usually apply single phase flow within the fluidic 
channel, i.e., the multiple fluids within the channel are miscible with each other. And in the 
following section, we will focus on another fundamental flow regime for microfluidics: 
multiphase flow, which is composed with two or more immiscible phases, more specifically, 
immiscible liquid/liquid systems. 
The prevailing applications for multi-phase flow based microfluidic devices are micro-particles 
or droplets production, despite there are also nano-emulsions feasibly fabricated via 
microfluidics.[100] The challenges for producing nano-droplets or emulsions come from the flow 
dynamics within the microfluidics channel and the mechanisms of droplet production. For 
nanoemulsion, the free energy of the droplets is higher than the free energy of the separate 
phases, which means that nanoemulsion is thermodynamically unstable. And the preparation 
process usually requires a strong energy input. Based on the equation (Eq. 10) proposed by 
Gupta et al.,[101] 











0.5                                 (10) 
where ε is the input energy intensity, μc and μd separately represent for the viscosity of 
continuous and dispersed phase, ρc and ρd separately represent for the density of continuous and 
dispersed phase, σ is the interfacial tension, c is a constant and d is the diameter of the emulsion. 
For a typical O/W emulsion with the size 100 nm, ε is on the order of 108–1010 W kg-1, which 




emulsions can significantly reduce the necessary energy input, as such more suitable for 
conventional microfluidics production. 
3.1. Microfluidics production of microparticles: advantages over conventional methods 
The adaptation of microfluidics to the production of microsized systems has become more 
popular since the first research work made more than 10 years ago.[102] The main reasons of the 
adoption of this technology stem from the homogeneity of the emulsions and the high degree 
of control over the process.[103-105] The control over the whole production process is possible 
due to the properties of the fluids in the microfluidic channels. 
The conventional production of microemulsion and microparticles is based either on high- or 
low-energy methods. High energy methods (e.g. high shear homogenizers and sonication) form 
emulsions by introducing high shear forces to disrupt the phases, leading to their mixing.[106] 
The formation of one emulsion is not a spontaneous phenomenon: it requires energy 
contribution to compensate the energy loss associated with an increase in the surface area.[107] 
The energy required to expand the surface can be described according to Eq. (11): 
∆G=∆Aγ-T∆S                                                                        (11) 
where, the free energy of formation (ΔG) is assumed positive due to the positive contribution 
of the energy to increase the interfacial area (ΔAγ), given by the increase in the area (ΔA) 
multiplied by tension at the interface (γ), with a minimal contribution from the entropy, 
resulting from the dispersion. 
The dimension of the emulsion droplets produced in bulk is regulated by the interplay of two 
different processes: droplets breakdown and droplets coalescence.[108] The breaking down of 
the droplet happens if the shear applied by the instrument is bigger than the Laplace pressure 




the inside and outside of the emulsion droplets) for a spherical droplets is described, according 
to Eq. (12): 
p=2γR                                                                  (12) 
where, the pressure p equals the radius of the spherical droplet multiplied by interfacial tension. 
Eq. (12) justifies the need for high energy required to deform, and eventually break-up the 
spherical dropswhich is reflected in higher Laplace pressure, and thereby, higher energy 
needed. An important descriptor of deformation in the droplets is the Weber number (We), 
defined by Eq. (13): 
We=Gηr2γ                                                              (13) 
where, the We is correlated with the ratio of the external shear given to the system (G is the 
velocity gradient and η is the viscosity) on the Laplace pressure (2γr). This number increases 
with the augment in the deformation, thereby higher energy is needed to produce smaller 
emulsions.[107] Taylor’s Eq. (14) allows precise estimation of the size of the droplets when the 
viscosity of the continuous phase is negligible and the system contains a low percentage of the 
dispersed phase: 
                                                                  r∝
γ
ηγ´
                                                               (14) 
where, the size (radius, r) is proportional to the ratio between the interfacial tension (γ) divided 
by the viscosity of the continuous phase (η) multiplied by the shear rate (γ’). Taylor’s equation 
helps understand the role played by the surfactant in the process: the role of a surfactant is to 
decrease the surface tension (γ), which is directly proportional to the radius of the droplet. 




stabilization of the emulsion itself, given by the positioning of the surfactant molecules at the 
interface between droplets and continuous fluid, which can effectively prevent the coalescence 
of the droplets.[108]  
Different theories have been proposed to describe the mechanisms behind this observed 
phenomenon, namely a stabilization due to the Gibbs-Marangoni’s effect in the early stages of 
emulsification, electrical repulsion, solvation barrier, viscosity of the surfactant solution, and 
hydrodynamic barrier to the flow of continuous fluid in the thin layer between two emulsion 
droplets. However, the general mechanism of stabilization is mediated by the balance between 
the reduction in the interfacial area derived from the merging of two droplets with the interfacial 
tension constant. In presence of a surfactant, the interfacial tension varies if the rate of the 
coalescence between the two droplets is faster than the rate of desorption of the surfactant from 
the interface, which results into an imbalance in the equilibrium of the adsorption. This leads 
to an increase in the chemical potential of the surfactant that can be alleviated only by either 
desorption of the surfactant molecules from the interface or from an increase in the interfacial 
area, counterbalancing the tendency to coalesce.[109]  
For single-phase flow facilitated NPs production, as discussed in section 2, the chip geometry 
is majorly composed by co-flow, whereas multiple geometries have been designed for 
microparticles production, and the mechanisms of droplet formation in microfluidics are 
generally dependent on the type of chip, its characteristics, and the attributes of the fluids. The 
different chip geometries exploited in the development of droplet-based emulsions and 
microparticles have been reviewed elsewhere.[72, 103] Briefly, as presented in Figure 7, the most 




focusing, co-flow, and different combinations of the previous for the production of double 
emulsions.[104]  
 
Figure 7. Most commonly employed device configurations in droplet-based microfluidics. 
(ac) Single emulsion with flow focusing and co-flow (a,b) applicable to both glass capillary 
and 2D chip, while T-junction (c) is proper only of 2D PDMS devices. (bg) Double emulsion 
configurations: as for glass capillary-based devices, combinations of co-flow with flow 
focusing, co-flow followed by co-flow, or multiple inner flow are reported (d-f), while for 2D 
devices, geometries combining co-flow with T-junctions or Y-junction combined with T-
junction. (h) Microfluidic channel configuration for producing Janus particles. Reproduced 
with permission from ref. [103], Copyright 2017, Royal Society of Chemistry. 
 
The main parameters having an effect on the fluids behavior have been presented above and are 
the Peclet number, Re, and capillary number (Ca). Ca describes the ratio between the viscous 
forces of the fluid over the surface tension, according to Eq. (15): 










where,  is the dynamic viscosity of the fluid,  is the velocity of the fluid, and  is the surface 
tension.[110] The dynamic viscosity is given by the static viscosity, , multiplied by the velocity 
of the fluid.  
The capillary number is of particular importance in droplet-based microfluidics. because it 
allows the investigation of different break-up patterns described by different ranges of capillary 
numbers.[111] In the case of low values of the capillary number (range < 10-2), the formation of 
the droplet is not influenced by the shear stress and it is only dependent on the accumulated 
pressure in the inner channel to form a thread and ultimately squeeze out the droplet. [112] The 
droplet formation will occur when the maximum extension of the droplet is higher than 1, 
according to Rayleigh-Plateau instability.[113] A useful implementation of the capillary number 
(extensional flow capillary number) can help distinguish between breaking and non-breaking 
parameters. To allow this, the radius of the droplet needs to be included amongst  the parameters 
on the numerator of the Ca number fraction.[113] However, according to other simulations, the 
droplet formation has been shown to be independent from the capillary number and to rely on 
the geometrical characteristic of the device, viscosity of the oil phase and the contact angle 
between the two phases.[114] This alternative model accurately describes the droplet formation 
at low flow rates. Furthermore, the first and the second model can be integrated considering the 
extensional flow capillary number, defined in Eq. (16):[113] 
                                                                 CG=Ca/w0                              (16) 
where, CG is the geometrical parameter and w0 is the width of the channel. 
In the case of class capillary microfluidics, the droplet formation is achieved in two different 




that the forces influencing the perturbation of the fluid are fixed, resulting in a system-intrinsic 
frequency. On the contrary, in jetting conditions, the perturbations are amplified throughout the 
fluid, leading to higher polydispersity of the droplets.[115] By carefully adapting the parameters 
(increasing the inner flow rate until a threshold where the inertial forces are higher than the 
surface tension) the propagation of the oscillations occurs in a capillary wave fashion, leading 
to the pinching of the droplet.[115] The careful optimization of the inner and outer fluid velocity 
allows the production of homogenously dispersed droplets even in jetting regimen.[115] 
3.2. Moving from colorful droplets to artificial cells and bioreactors 
The initial and one of the most important applications of microfluidics produced microparticles 
or droplets are encapsulating bioactive compounds, including small molecule drugs, 
peptides/proteins and DNA/RNA. Several reviews have been proposed previously to 
summarize microfluidic fabrication of microparticles for drug loading/delivery applications.[116] 
Yet, inspired by the recent evolving molecular biological concepts and techniques, 
microfluidic-produced micro-particles and droplets may also become an alternative platform 
for multiple applications. 
The first proof-of-concepts in droplet-based microfluidics have been focusing on the production 
of complex emulsions, visualized with the use of hydrophilic and lipophilic colors (Figure 8). 
Complex architectures have been created in glass capillary microfluidics by a careful 
engineering of the geometry of the capillary, to introduce elements in series or in parallel, and 





Figure 8. (a) Device geometries and process for the generation of triple emulsions. a. Schematic 
of the device with the different elements connected in series; bd. Micrographs of the different 
phases of the emulsification process (stage I to stage III); e. Micrographs of the produced 
emulsions, displaying the high control in the number of droplets added in each of the stages; f. 
Alternative configuration of the device eliminating the need for the middle fluid compartment; 
gj. Microphotographs of the improved process. (b) Double emulsion proof-of-concept of an 
innovative platform for the chip assembly. a. micrograph of the assembled device, running in a 
flow focusing configuration; b. and c. micrographs of the obtained emulsions. (c) Production 
of multiple layers of polymers in a 2D device with a double T-junction configuration. a. 
Schematic of the device with the elements in series; b. and c. Micrographs of the obtained gels, 
highlighting the effect of the different parameters on the shell thickness. d. Spatially-resolved 
profiles of the fluorochromes to investigate the interpenetration between the two polymers. 




(b) ref. [118], Copyright 2016, Elsevier; (c) ref. [119], Copyright 2010, American Chemical 
Society. 
 
These proof-of-concepts have been of the utmost importance in the exploration of the ranges of 
parameters producing complex systems, facilitating their further development. The engineering 
of devices like the one presented in Figure 8a enables the control over every single module in 
terms of frequency of droplets produced in each module. The range of capillary numbers has 
been selected to achieve the droplet break-up under conditions of absolute instability, or 
dripping, allowing to predict the size of the droplet by calibrating the flow rate of the outer 
fluid.[117] Moreover, the authors reported empirical relationships between the diameter of each 
layer of droplets and the flow rate that resulted into a control over the desired number of droplets 





























3                                          (17) 
where, the number of inner droplets (N1) is predicted by the control over the flow rates of the 
different modules (f1 and f2 being the formation rates of the inner and outer droplets, Q1 and 
Q2, the flow rates of inner and outer fluid, respectively, and d the diameters of inner of outer 
droplets).[117] As evident from Eq. (17), a careful adjustment of the flow rates between the 
different modules is governing the type of complex structure obtained (Figure 8a).  
The proof-of-concept has been employing rather straightforward to inner and outer solutions 
like poly(dimethylsiloxane) oil, octanol, glycerol, kerosene, all containing 1-3% of surfactants 




phase.[117, 118] Additionally, colorants were used to help visualize both the flows and droplet 
formation within the device and the final structure of the vesicles (Figure 8b), such as trypan 
blue can be added to water phase, while nile red can stain oil phases.[118] 
Importantly, the production of complex structures by microfluidics is not limited to glass 
capillary devices. Soft lithography-printed devices (like PDMS) can produce homogeneous 
droplets by flow focusing[120] or geometrically-mediated breaking (T-junctions).[113, 121] As 
presented in Figure 8c, T-junction devices can be engineered to produce core-shell 
structures.[119] Once again, as demonstrated for the glass capillary devices, the number of inner 
droplets within the outer shells and the thickness of the shell are controlled by the flow rates of 
the inner, middle and outer phases.[119] However, these devices are less robust towards organic 
solvent when compared to the glass capillary ones.[122] 
3.2.1. Microvesicles: from polymerosomes to artificial cells 
The first examples of applications for the microdroplets have been in the development of 
vesicles or solid microparticles for drug delivery.[103, 122] Vesicles (e.g., polymerosomes and 
liposomes) can be defined as an enclosure of fluid surrounded by a bilayer of amphiphilic 
molecules.[122] The conventional preparation methods are co-solvent method (solvent switch, 
where the amphiphilic molecules are dissolved in organic solvent, before gradually adding an 
aqueous solution), film rehydration method (organic solvent is used to dissolve the amphiphilic 
molecules, before being completely evaporated, creating a film of the amphiphiles, ready to be 
rehydrated with aqueous solutions), and direct dissolution method (amphiphiles precipitate in 
the water solution, followed by a self-assembly process).[123] Each of these methods lead to a 





However, vesicles can be easily produced by double emulsions templates in microfluidics: the 
amphiphilic molecules are dissolved within the organic middle phase in a water-in-oil-in-water 
emulsion setup.[122, 124] The optimization of the flow conditions affects the radius of the 
emulsion droplets, thereby the size of the final vesicles. The proof-of-concepts have led to the 
development using diblock copolymers (e.g., poly(n-butyl acrylate)-poly(acrylic acid) and 
phospholipids) in tetrahydrofuran that self-assemble at the interfaces between the water and oil 
interfaces (Figure 9a).[125, 126] Lipidic vesicles have also been produced via T-junction droplets 
breaking (Figure 9b).[127] Importantly, the viscosity of the outer water phase helps improving 
the flow focusing geometry, while the volatility of the organic solvent favors the self-assembly 
of the amphiphiles, facilitating the formation process.[125, 128] Two different mechanisms have 
been proposed for the formation of the vesicles from the double emulsion: the evaporation of 
the organic solvent induces the formation of a depletion force, which in turn initiate the 
dewetting process (Figure 9c).[129] However, the process is highly influenced by the speed of 
the evaporation in the final dewetting stage, which may break the vesicles.[126] Thereby is of 
paramount importance to control the speed of the solvent removal. This can be controlled 
through a control on the concentration of the organic solvent in the outer solution that is also 
directly correlated with the final size of the vesicles (the longer the time allowed for the 
dewetting-evaporation process, the smaller the vesicles).[126] Another way to control the size of 
the vesicles or the final PLGA microparticles was demonstrated by Tu et al. through osmotic 
annealing.[130] The annealing is controlled by the concentration of a solute in the water phases 
(inner and outer). Thereby, to control the tension on the vesicle is by having the dewetting in 
concentrated glycerol solutions (80% and above).[126] A second mechanism proposed for the 
formation of the vesicles is the pinning of the amphiphiles to the inner water vesicles, allowing 





Figure 9. (a) Proof-of-concept of the dewetting of double emulsions obtaining polymerosomes. 
AC. Micrographs of the organic solvent evaporation; D. Micrograph of the final polymersome. 
(b) Engineering of phospholipidic bilayer vesicles via T-junction microfluidics. Schematic of 
the vesicle formation process. (c) Proposed dewetting mechanism for the formation of 
phospholipid vesicles starting from double emulsions: during the solvent evaporation, the 
phospholipids dissolved in the middle organic phase reassemble at the interfaces between the 
oil and the water phases, creating a bilayer phospholipidic vesicle. (d) Suitability of thin-layer 
double emulsion technique for the production of functional models of cell membrane. The 
produced vesicles presented membrane heterogeneity and could accommodate a pore forming 
protein (-hemolysin) as illustrated in the scheme and confirmed by the gradual accumulation 
of sulphorhodamine entering through the pores created by the protein. Figures are reproduced 




[127], Copyright 2009, WILEY‐VCH. (c)  ref. [126], Copyright 2008, Americal Chemical Society; 
(d) ref. [131], Copyright 2013, WILEY‐VCH. 
 
Recently, micro-sized vesicles (mainly giant unilamellar vesicles) have surged to a new role as 
ideal models of artificial cells and cell membrane.[132] The advantages derived from the use of 
microfluidics technique for their production reside mainly in the degree of control achievable 
on size, lamellarity, membrane composition, and payload.[131, 133, 134] At the same time it is 
possible to produce high number of such vesicles, reducing the overall costs.[133] [133, 135] A 
downside of the production of giant unilamellar vesicles by double emulsion in microfluidics 
is the lacking heterogeneity in the composition of the membranes.[131, 136] While cells and 
artificial membranes produced through conventional methods show high membrane 
heterogeneity with the presence of lipid rafts, the presence of organic solvents and the 
production process in microfluidics leads to the production of homogenous vesicles. A careful 
selection of the volatility of solvents employed in the middle organic phase results in the 
formation of heterogenic domains, with the possibility to insert membrane proteins, like the 
pore-forming -hemolysin (Figure 9d).[131] Alternatively, giant unilamellar vesicles can be 
produced with MHz yield through droplet stabilization with the possibility to inject 
biomolecules through pico-injection.[137] In particular, the formation of the vesicles is promoted 
by the injection of Mg2+ ions within the droplets, promoting the formation and the release of 
the vesicles.[137] Interestingly, however, by mechanical compressing the giant unilamellar 
vesicles, Robinson et al. observed a spontaneous rearrangement of the lipid domains 




Artificial cells and artificial cell membranes help in the breaking down of the complex cellular 
machine, one mechanism at the time to better understand their function.[133] [133, 138] However, 
the complexity of the cellular environment has proven difficult to recreate either in terms of 
membrane features (as discussed above) or in terms of intracellular organelles complexity. 
Cytoskeleton is one of the cellular features that researchers have tried to mimic; natural 
components of the cytoskeleton have been loaded within the vesicles, or the rigidity of the 
cytoskeleton has been provided by hydrogels.[139, 140]  
 
Figure 10. (a) Controlled formation of alginate microfilaments and their encapsulation within 
vesicles to mimic the cytoskeleton fibers. 1)4) Micrographs of the process of fiber 
encapsulation within the droplets; 5) Comparison of the size distribution between empty and 
fiber-loaded vesicles; 6)7) Micrographs collected at different time points, showing that the 
fiber maintains its shape and dimension over time, confirming the success of the gelation 
process. (b) Engineering of dumbbell-shaped polymerosomes, creating two compartments with 




polymerosomes production within the chip. 3) Schematic of the structure of the dumbbell 
polymerosomes. 4)5) Confocal micrographs of the dumbbell-shaped polymerosomes 
highlighting the two different types of hydrogels loaded (different fluorochromes). 6) Release 
behavior in ultrapure water over time. Figures are reproduced with the permission from: (a) ref. 
[140], Copyright 2016, Royal Society of Chemistry; (b) ref. [141], Copyright 2013, WILEY‐VCH. 
In one interesting example, the cytoskeleton fibrils microtubules have been mimicked by 
alginate microfibers (Figure 10a). Both the synthesis of the microfibers and their encapsulation 
within the vesicles have been performed within the same device.[140] The length of the alginate 
fibers can be controlled through the application of a pulsatile pressure regimen in the first 
sheathing buffer, effectively cutting the fiber off at the desired length. The gelation of the fiber 
is achieved further down the channel, with the input of a second buffer solution containing Ca2+ 
ions, before a single-step emulsification into the final vesicle.[140] In the setup conditions, only 
one in three droplets presented a fiber encapsulated due to a difficult interfacing between the 
pulsatile conditions required for the cutting of the fiber and the controlled flow rate demanded 
for the droplet formation. Contractility movements of vesicles loaded with microtubulues and 
its dependency on ATP has also been shown.[142] The intracellular elastic module can also be 
achieved through the use of hydrogels with different stiffnesses.[143] However, different 
intracellular compartment present different stiffness together with different payload. Dumbbell-
shaped polymerosomes can offer a partial solution by enabling the selection of different payload 
and stiffness in each of the two compartments through the two parallel flows of the inner water 
phase.[141] Alternatively, the formation of actin filament and microtubules was achieved through 
picoinjections of G-actin and tubulin, together with polymerization buffers, within droplet 
stabilized giant unilamellar vesicles.[137] 




be reliably achieved by trapping the droplets in 3D structures in PDMS systems.[144] By 
applying different flow rates, modifying the dimensions of the trap, pr creating different 
pressures thanks to transmembrane osmotic pressure, this systems can produce bacteria-like 
vesicles, discoidal-like cells, and achieve an orientation-controlled alignment of protein fibers 
(microtubules or collagen) within the artificial cells.[144]  
The proof-of-concept design of multiple droplets within the same emulsion have inspired 
vesosomes mimicking  the organelles structure and have been investigated as bioreactors.[145] 
In particular, Deng et al. have investigated different configurations of the devices to answer to 
different needs of the artificial cell models, including a protein-mediated self-assembly of 
organelles.[146] The double emulsions vesicles have been prepared by phospholipidic bilayer, 
stabilized by PEG, PVA and pluronic as surfactants in the water phases. The control over the 
different structures achieved was obtained by a control over the flow rate of the different phases, 
according to the empirical Eq. (17). However the downside of their technique is the 
impossibility to modify the compartments after production, which may be solved by modifying 
picoinjection methods.[147] In a simpler design, Ugrinic et al. developed proteinosomes, vesicles 
formed by proteins conjugated with poly(N-isopropylacrylamide) to render them 
amphiphilic.[148] The proteins forming the shell of the vesicles have been proven to be functional 
and, by loading into the vesicles proteins or enzymes constituting the following step in the 
signal cascade, multiple step enzymatic reactions could be performed.[148] 
Finally, taking advantage from the possibility of modifying single-strand DNA into DNA 
origami, intracellular lipidic moieties can be inserted within the artificial cells by DNA 





The future of artificial vesicles resides in the development of novel methods to improve the 
yield and the maturation time of the vesicles [135] or in the encapsulation of living cells within 
the vesicles to serve as bionic organelles.[149] Alternatively, microfluidic-based artificial cells 
can model the interaction between viruses and host cells, allowing for the high throughput 
screening of antiviral compounds within the picoliter volume of the vesicle.[150] Multiple 
questions remain about the possibility to formulate an universal “cytoplasmatic” buffer, about 
the different methodologies to deliver different payloads in succession, to the construction of 
complex intracellular structures. 
 
3.2.2. Microparticles and microcapsules: from drug delivery to bioreactors 
The controlled emulsion droplets obtained in microfluidics serve also as excellent template for 
solid particles.[151] Given that the starting template is still constituted of emulsions, the control 
over the size, the homogeneity, and the structure of the particle is mediated by the geometry of 
the device and the control over the flow rate of the different phases flowing within the chip. 
The simplest examples of solid particles are derived from single emulsion templates, with the 
production of a solid matrix-like particle after solvent evaporation and dewetting (Figure 
11a).[152] Such systems are formulated from polymers (e.g., PLGA) or lipid dissolved in the 
organic phase, with a surfactant added to the water phase to stabilize the emulsion droplets.[152, 
153] Drug, imaging agent, micro- and nano-particles are amongst the first payloads evaluated 
within possible biomedical applications as therapy or imaging agent (Figure 11b).[103, 154] More 
complex structures, including core-shell, capsules, porous particles have been engineered from 




focused on the release profile of the payload from the particle, important for drug delivery 
applications.[103]  
 
Figure 11. (a) Micrograph of solid polymeric particles derived from single emulsion droplets. 
(b) Loading of nanoparticles within the polymeric matrix formed by single emulsion. A. 
Schematic of the different stages of the production process; b. Confocal micrographs showing 
the homogeneity of the particles and the homogenous dispersion of the nanoparticles (FITC, 
green) within the polymeric matrix; c. Dissolution study of the microparticles over time at pH 
7.4, illustrating the degradation profile of the system. (c) Core-shell particles obtained by double 
emulsion microfluidics. a. Schematic of the device engineered for the production of the double 
emulsions; bd. Micrographs showing the formation of the inner droplets and the double 
emulsion; e. Schematic illustrating the template for the formation of the hole. Figures are 
reproduced with the permission from: (a) ref. [152], Copyright 2009, Wiley‐VCH; (b) ref. [154], 





Emulsion droplets and microcapsules can serve also as microreactors, performing multiplex 
chemical or biological reactions on a small scale and with smaller consumption of reagents.[150, 
157] In particular, biological reactions, such as the widening of the polymerase reactions.[158] The 
flow rate of both inner and outer phases have to be calibrated to ensure that each single droplet 
contained only one bacteria. After collecting the emulsions and performing the reaction, the 
droplets are run a second time through the chip, to create a water-in-oil-in-water (w/o/w) 
emulsion easy to be read with instruments like flow cytometers (Figure 12a). [158] Droplets 
microfluidics can also encapsulate cells for counting, further analysis, or for biomedical 
applications, with the caveat that, starting from a suspension of cells, their distribution in the 
droplets will follow a Poisson distribution.[7] Thereby, on top of the control over the geometry 
of the device and the flow rates, a calculation and control over the concentration of the cells in 
the volume of the initial droplet is also required to avoid empty droplets.[150] Each droplet can 
be barcoded to identify the droplet and its composition in the readout (Figure 12b).[159] 
However, in particular applications, like the prolonged culture of cells structures, droplet 
emulsions are not considered the optimal mean, with hydrogel microcapsules representing the 
alternative (Figure 12c).[160] Finally, multistep chemical and biological reactions can take place 





Figure 12. (a) Two-stage process for the improvement of polymerase chain reaction (PCR) 
reaction via droplet microfluidics. (b) Single-chip PCR reaction of encapsulated cells. a. 
Schematic of the process; b. Micrographs of the various on-chip steps.  (c) On-chip cell 
encapsulation in hydrogels microcapsules. (d) Schematic of a multistep on-chip chemical 
reaction. Figures are reproduced with the permission from: (a) ref. [158], Copyright 2016, the 
authors, under a Creative Common Attribution 4.0 International License. (b) ref. [161], Copyright 
2018, Pellegrino et al.; Published by Cold Spring Harbor Laboratory Press, under a Creative 
Common Attribution 4.0 International License. (c) ref. [160], Copyright 2017 Acta Materialia 
Inc. Published by Elsevier Ltd. (d) ref. [162], Copyright 2014, the authors, under a Creative 
Commons Attribution 3.0 Unported License. 
 
4. Conclusions and future perspectives 
Here, we have presented an overview of the basic mechanism and application of microfluidics 
for the production of both nano- and micro-particles or droplets with potential biomedical 
applications. Featured with identical properties, such as higher reproducibility, precisely 




processes, microfluidic platforms have unique advantages that may facilitate the clinical 
translation of cutting-edge technologies, including nanomedicines, single cell analysis and 
artificial cells. From an engineering point of view, for microfluidics-based nanoparticles 
fabrication, we have addressed the rationale of the advantageous features from microfluidic 
produced nanoparticles, and we highlighted the recent progresses of using microfluidics to 
synthesize nanoparticles with identical core/shell structures. Despite the prosper progress in 
core/shell nanoparticles fabrication and the following biomedical research, further work should 
be focused on unravel the mechanism of the core/shell structure formation, which may provide 
insights for guiding the nanosystem design. For microfluidics based micro-particle/droplets 
synthesis, we also illustrated the principle of design for microfluidic assisted micro-droplet 
production. In addition to their long established applications for drug encapsulation and 
delivery, we highlighted the integration of microfluidic produced micro-droplets in cellular 
analysis and simulation. We conclude that the future will see the mainstream application of 
droplet microfluidics to the high throughput screening of new drugs, and will allow the daily 




Z. Liu acknowledges the financial support from Chinese Scholarship Council (CSC). F.F. 
acknowledges the Faculty of Pharmacy of the University of Helsinki for an assistant research 
grant. H.A.S. acknowledges financial support from the Sigrid Jusélius Foundation and the 
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Microfluidics for production of particles: mechanism, methodology and applications 
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 As a fundamental compartment, micro- and nano-particles or droplets have been extensively 
applied for biomedical usages. A review of microfluidic produced nano-, micro-particles or 
droplets and a brief summary of their corresponding mechanism and production is presented. 
Previous mechanical theories are explained, current tendency of their actual application is 
discussed and the future perspectives and limitations are proposed. 
 
